iBio, Inc.
iBio, Inc. (IBIO) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for iBio, Inc. (IBIO), featuring income statements, balance sheets, and cash flow data.
iBio, Inc. (IBIO) Income Statement & Financial Overview
Explore comprehensive income reports for iBio, Inc. IBIO, broken down by year and quarter.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $200000.00 | $0.00 | $175000.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | -$744000.00 | $332000.00 |
| Gross Profit | $200000.00 | $0.00 | $919000.00 | -$332000.00 |
| Gross Profit Ratio | $1.00 | $0.00 | $5.25 | $0.00 |
| R&D Expenses | $1.88M | $1.30M | $1.14M | $904000.00 |
| SG&A Expenses | $2.74M | $2.80M | $2.44M | $2.39M |
| Operating Expenses | $4.62M | $4.11M | $3.58M | $3.29M |
| Total Costs & Expenses | $4.62M | $4.11M | $3.58M | $3.63M |
| Interest Income | $112000.00 | $174000.00 | $223000.00 | $43000.00 |
| Interest Expense | $57000.00 | $57000.00 | $60000.00 | $52000.00 |
| Depreciation & Amortization | $281000.00 | $278000.00 | $281000.00 | $332000.00 |
| EBITDA | -$4.03M | -$3.65M | -$2.90M | -$2.25M |
| EBITDA Ratio | -$20.13 | $0.00 | -$16.60 | $0.00 |
| Operating Income | -$4.36M | -$4.11M | -$3.41M | -$3.63M |
| Operating Income Ratio | -$21.82 | $0.00 | -$19.48 | $0.00 |
| Other Income/Expenses (Net) | $0.00 | $117000.00 | $163000.00 | $991000.00 |
| Income Before Tax | -$4.36M | -$3.99M | -$3.25M | -$2.63M |
| Income Before Tax Ratio | -$21.82 | $0.00 | -$18.55 | $0.00 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $537000.00 |
| Net Income | -$4.36M | -$3.99M | -$7.78M | -$3.17M |
| Net Income Ratio | -$21.82 | $0.00 | -$44.45 | $0.00 |
| EPS | -$0.48 | -$0.46 | -$0.90 | -$0.85 |
| Diluted EPS | -$0.48 | -$0.46 | -$0.90 | -$0.85 |
| Weighted Avg Shares Outstanding | $9.13M | $8.63M | $8.62M | $3.71M |
| Weighted Avg Shares Outstanding (Diluted) | $9.13M | $8.63M | $8.62M | $3.71M |
The company's financials show resilient growth, with revenue advancing from $0.00 in Q3 2024 to $200000.00 in Q2 2025. Gross profit remained healthy with margins at 100% in Q2 2025 compared to N/A in Q3 2024. Operating income hit -$4.36M last quarter, sustaining a consistent -2182% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$4.03M. Net income dropped to -$4.36M, while earnings per share reached -$0.48. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan